Lutetium (177Lu) zadavotide guraxetan is under clinical development by POINT Biopharma Global and currently in Phase III for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According to GlobalData, Phase III drugs for Metastatic Castration-Resistant Prostate Cancer (mCRPC) have a 44% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Lutetium (177Lu) zadavotide guraxetan’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Lutetium (177Lu) zadavotide guraxetan overview
Lutetium (177Lu) zadavotide guraxetan (PNT-2002) is under development for the treatment of metastatic castration resistant prostate cancer and oligorecurrent prostate cancer. It is administered through intravenous route. The drug candidate consists of PSMA ligand conjugated with lutetium 177 and acts by targeting cells expressing PSMA. It is being developed based on canSEEK technology.
POINT Biopharma Global overview
Point Biopharma Global (Point Biopharma), formerly Therapeutics Acquisition Corp, is a radiopharmaceutical company. It develops and commercializes radioligands for cancer. The company invests in PNT2002 against mCRPC (metastatic castration resistant prostate cancer), PNT2003 program to treat neuroendocrine tumors, PNT2004 targeting solid tumors expressing FAP (fibroblast activation protein), and PNT2001 against prostate cancer. It utilizes CanSEEK platform technology to develop cancer treatments. The company’s technology aims to minimize toxicity caused by off-target delivery by activating radiopharmaceuticals that target ligands. It is a subsidiary of Eli Lilly and Co is headquartered in Indianapolis, Indiana, the US.
For a complete picture of Lutetium (177Lu) zadavotide guraxetan’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
